Rafferty Asset Management
BHVN

Rafferty Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Rafferty Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-45,902
Closed -$6.94M – 1181
2022
Q3 		$6.94M Buy
45,902
+19,423
+73% +$2.88M 0.07% 227
2022
Q2 		$3.86M Sell
26,479
-18,522
-41% -$2.37M 0.04% 337
2022
Q1 		$5.34M Sell
45,001
-7,875
-15% -$982K 0.03% 375
2021
Q4 		$7.29M Buy
52,876
+29,720
+128% +$3.78M 0.04% 257
2021
Q3 		$3.22M Sell
23,156
-1,681
-7% -$210K 0.02% 438
2021
Q2 		$2.41M Sell
24,837
-16,031
-39% -$1.3M 0.02% 623
2021
Q1 		$2.79M Buy
40,868
+30,188
+283% +$2.44M 0.02% 533
2020
Q4 		$915K Sell
10,680
-22,928
-68% -$1.94M 0.01% 528
2020
Q3 		$2.19M Buy
33,608
+19,137
+132% +$1.25M 0.03% 391
2020
Q2 		$1.06M Buy
14,471
+7,631
+112% +$406K 0.01% 530
2020
Q1 		$233K Sell
6,840
-51,203
-88% -$2.34M 0.01% 490
2019
Q4 		$3.16M Sell
58,043
-67,735
-54% -$3.35M 0.05% 212
2019
Q3 		$5.25M Buy
125,778
+48,518
+63% +$2.05M 0.08% 148
2019
Q2 		$3.38M Buy
77,260
+20,951
+37% +$1.18M 0.06% 240
2019
Q1 		$2.9M Buy
+56,309
New +$2.43M 0.05% 230

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Rafferty Asset Management's BHVN Position: Q4 2022 in Review

Rafferty Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 45,902 shares — an estimated $6.94M sold.

Rafferty Asset Management first reported a position in BHVN in Q1 2019 and held it in 15 quarters. The position peaked at $7.29M in Q4 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Rafferty Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Rafferty Asset Management sold 45,902 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $6.94M.
  • Rafferty Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 15 quarters.
  • Rafferty Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $7.29M in Q4 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Rafferty Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.